Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Phosphatase inhibitors act on protein, lipid and inositol phosphatases that hydrolyze phosphate esters. A 2004 survey of the human genome counted 107 genes for protein tyrosine phosphatases (PTPs). Serine/threonine phosphatases such as protein phosphatases 1 and 2A (PP1, PP2A) reverse many kinase-driven signals. Calyculin A, reported in 1989 as an inhibitor of protein phosphatase activity, blocks both PP1 and PP2A. LB-100 targets PP2A, tautomycetin prefers PP1, and sodium orthovanadate inhibits PTPs broadly and is a common lysis buffer additive. Among lipid and inositol phosphatases, 3AC inhibits Src homology 2 (SH2) domain-containing inositol 5-phosphatase 1 (SHIP1), and L-690330 targets inositol monophosphatase.
Synonyms: Acetyl ceramide; N-Acetyl-D-sphingosine
Ceramide is a ceramide shown to be a potent modulator of proliferation and differentiation, used as a tool for studying the complex signaling associated with the ceramides.
PROTAC PTPN2 degrader-1 is an effective degrader of the protein tyrosine phosphatase PTPN2. This compound facilitates target protein degradation through the proteasome pathway, enabling the modulation of cellular signaling related to cancer and metabolic diseases. Its application in research may provide insights into the therapeutic potential of targeting PTPN2 in various disease contexts.
Anticancer Agent 7 is a PP2A modulator that facilitates the translocation of the FOXO1 transcription factor to the nucleus. This compound exhibits significant anti-proliferative activity against H1650 lung cancer cells, demonstrating an IC50 value of 5 μM. It serves as a valuable tool in cancer research, particularly in studies focused on signaling pathways involving PP2A and FOXO1.
